Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Moderate to Severe Rheumatoid Arthritis (RA-BEAM)
NCT01710358Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2012
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 28
01
Overview
A Phase 3 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Oct 2012; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01710358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01710358.